Supercharged immune cells take on deadly brain tumors

NCT ID NCT07551336

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new treatment for people with recurrent glioblastoma, a fast-growing brain cancer. The treatment uses a patient's own immune cells (NK cells) that have been engineered in a lab to better recognize and attack tumor cells. The cells are delivered directly into the brain. The study aims to find a safe dose and see if the treatment can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Dual-targeting CAR-NK cells (immune cells engineered to recognize and attack brain tumor cells)
What this could lead to
If this works, it could point toward a new treatment option for people with recurrent glioblastoma, a type of brain cancer that is very hard to treat.
What could go wrong
This is a very early (phase 1) and small trial (36 people). The main goal is safety, not effectiveness. It may not work, and there are risks like severe immune reactions or brain swelling.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Peking University Shenzhen Hospital

    RECRUITING

    Shenzhen, Guangdong, 518036, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.